William Scully buys 110,000 shares. Analysts target Prothena stock at USD 24.57

Published on 10/18/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 1.01 million versus USD 0.42 million consensus. Eight analysts gave Prothena stock a Moderate Buy consensus on October 13, 2026.

Ownership and operating markers

William P. Scully bought 100,000 shares on October 13, 2026, and 10,000 shares on October 14, 2026.
Second-quarter 2026 revenue reached USD 1.01 million versus USD 0.42 million consensus.
Eight analysts held a Moderate Buy consensus with a USD 24.57 average target on October 13, 2026.

PRTA, IE00B91XRN20, Illustration mit AI erstellt.

Prothena Corporation plc (ISIN IE00B91XRN20) drew fresh attention after 10% owner William P. Scully bought 100,000 shares on October 13, 2026, and another 10,000 shares on October 14, 2026, according to StockTitan. The purchases came as analysts carried a Moderate Buy consensus and an average USD 24.57 target, MarketBeat reported on October 13, 2026.

October filings add two purchases

The chronology points to a concentrated ownership signal rather than a single transaction. On August 6, 2026, Prothena reported second-quarter revenue of USD 1.01 million against USD 0.42 million consensus, according to MarketBeat. On October 13, 2026, Scully bought 100,000 shares at a weighted average of USD 8.3548; on October 14, 2026, he bought 10,000 at USD 8.4569, according to StockTitan.

What does the buying mean for risk?

The purchases provide a concrete ownership signal, but they do not remove the biotechnology company's operating risk. Prothena's second-quarter 2026 net loss was USD 18.58 million, while revenue was USD 1.01 million, according to MarketBeat. The same report said the loss of USD 0.32 per share was better than the USD 0.39 consensus loss, leaving the investment case tied to clinical progress and future partnerships.

Nasdaq listing keeps the frame

Prothena describes itself as a clinical-stage biotechnology company developing therapies for diseases caused by protein dysregulation, including neurological and rare peripheral amyloid diseases, Prothena says. A regulatory filing dated October 2, 2026, identifies PRTA as listed on the Nasdaq Global Select Market and records the resignation of Chief Development Officer Chad J. Swanson effective October 9, 2026, the SEC filing states.

Ownership meets uneven results

The latest filings combine sizeable insider purchases with a quarter that exceeded revenue and adjusted earnings expectations but still produced a substantial net loss. That contrast leaves clinical execution and cash use as the central measures for the next company update. The further course of trading is shown by the continuously updated real-time quote of Prothena stock.